[Nr 110] Wpływ czynników prognostycznych na wyniki radiochemioterapii chorych na zaawansowanego raka szyjki macicy

Published on Nov 1, 2013in Zeszyty Naukowe WCO, Letters in Oncology Science
· DOI :10.1016/j.onko.2013.09.111
Żaneta Wareńczak-Florczak2
Estimated H-index: 2
H. Wlodarczyk2
Estimated H-index: 2
+ 1 AuthorsAndrzej Roszak9
Estimated H-index: 9
  • References (44)
  • Citations (0)
Background: This is a retrospective study evaluating the survival outcomes, patterns of failure, and prognostic factors of chemoradiotherapy incorporating high-dose rate brachytherapy in the treatment of locally advanced cervical cancer. Methods: A review of 120 consecutive patients with Federation Internationale de Gynecologie et d9Obstetrique (FIGO) stages IB2 to IVA cervical cancer treated with concurrent cisplatin-based chemoradiotherapy between April 1999 and January 2005. Overall (OS) and ...
16 CitationsSource
#1Dae Woo Lee (Yonsei University)H-Index: 7
#2Young Tae Kim (Yonsei University)H-Index: 36
Last. Jae Wook Kim (Kwandong University)H-Index: 9
view all 7 authors...
2 Objective: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy. Methods: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/m 2 ) and radiotherapy between January 2000 and April 2007. Potential prognostic factors were age, chemotherapy numbers, histology, tumor d...
22 CitationsSource
#1Lilian T. Gien (Sunnybrook Health Sciences Centre)H-Index: 13
#2Marie-Claude Beauchemin (Sunnybrook Health Sciences Centre)H-Index: 1
Last. Gillian Thomas (Sunnybrook Health Sciences Centre)H-Index: 47
view all 3 authors...
Adenocarcinoma of the cervix constitutes only approximately 20% of all cervical carcinomas; therefore, specific Level 1 evidence to guide patient management is lacking. Most trials have included this histologic subtype but in insufficient numbers to do more than generate hypotheses from subset analyses. As a consequence, our understanding of the natural history and optimal management of adenocarcinoma of the cervix is limited. The optimal management of adenocarcinoma of the cervix continues to b...
124 CitationsSource
#1Bengt SorbeH-Index: 25
#2Louise BohrH-Index: 1
Last. Berit BermarkH-Index: 1
view all 4 authors...
In a series of 131 primary cervical carcinomas in FIGO stages I-IV suitable for combined external pelvic and intraluminal cervical-vaginal brachytherapy predictive and prognostic factors were analyzed with regard to locoregional tumor control, recurrences and survival data. Patients with prior surgery or patients treated with external beam therapy alone were excluded from this series. Concomitant chemotherapy was given to 47 patients (36%). The external beam therapy was given with a four-field t...
9 CitationsSource
#1Michael C. JoinerH-Index: 43
13 CitationsSource
#2Garry ChoyH-Index: 18
Last. Susanna I. LeeH-Index: 22
view all 6 authors...
OBJECTIVE. We evaluated the ability of pretreatment MRI and PET/CT to improve outcomes for patients with clinically staged International Federation of Gynecology and Obstetrics (FIGO) IB cervical cancer.MATERIALS AND METHODS. We developed a decision-analytic model to predict outcomes for a hypothetical patient cohort with FIGO IB cervical cancer who underwent pretreatment MRI, PET/CT, MRI and PET/CT, or no further imaging (direct pursuance of surgery). The model incorporated imaging performance,...
34 CitationsSource
#1Hedvig Hricak (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 107
#2Constantine Gatsonis (Brown University)H-Index: 77
Last. Donald G. Mitchell (Thomas Jefferson University)H-Index: 60
view all 10 authors...
Purpose: To retrospectively compare diagnostic performance and interobserver variability for computed tomography (CT) and magnetic resonance (MR) imaging in the pretreatment evaluation of early invasive cervical cancer, with surgical pathologic findings as the reference standard. Materials and Methods: This HIPAA-compliant study had institutional review board approval and informed consent for evaluation of preoperative CT (n = 146) and/or MR imaging (n = 152) studies in 156 women (median age, 43...
113 CitationsSource
#1Richard Pötter (Medical University of Vienna)H-Index: 61
#2Christine Haie-Meder (Institut Gustave Roussy)H-Index: 52
Last. Christian Kirisits (Medical University of Vienna)H-Index: 44
view all 13 authors...
The second part of the GYN GEC ESTRO working group recommendations is focused on 3D dose-volume parameters for brachytherapy of cervical carcinoma. Methods and parameters have been developed and validated from dosimetric,
921 CitationsSource
#1Diane M. Harper (Dartmouth College)H-Index: 35
#2Eduardo L. Franco (McGill University)H-Index: 81
Last. Gary Dubin (GSK: GlaxoSmithKline)H-Index: 39
view all 16 authors...
Summary Background Vaccination against the most common oncogenic human papillomavirus (HPV) types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers worldwide. We did a randomised, double-blind, controlled trial to assess the efficacy, safety, and immunogenicity of a bivalent HPV-16/18 L1 virus-like particle vaccine for the prevention of incident and persistent infection with these two virus types, associated cervical cytological abnormalities, and precancerous lesion...
1,443 CitationsSource
Oncogenic human papillomavirus (HPV) infections, the necessary cause of most cervical cancers, are common and usually clear within 1 to 2 years. Identifying cofactors that lead to cancer among HPV-infected women has depended mainly on case-control studies defining HPV by DNA testing. DNA testing assesses only current infection; thus, concerns about residual confounding remain. To assess cofactors, we used seropositivity to five oncogenic HPV types as a marker of past exposure and confined our an...
72 Citations
Cited By0